[PDF][PDF] Switching for convenience from first-line injectable treatments to oral treatments in multiple sclerosis: data from a retrospective cohort study
G Buard, J Giovannelli, O Outteryck, N Hadhoum… - Multiple sclerosis and …, 2019 - Elsevier
Teriflunomide (TRF) and dimethyl fumarate (DMF) recently changed prescription habits for
patients with multiple sclerosis (MS). Because these first-line treatments are oral, they are …
patients with multiple sclerosis (MS). Because these first-line treatments are oral, they are …
Real‐World Healthcare Cost Savings and Reduced Relapse Rate with Off‐Label Rituximab versus Disease‐Modifying Treatments Approved for Relapsing–Remitting …
Objective Although off‐label use of rituximab is a common alternative to disease‐modifying
therapies (DMTs) approved for multiple sclerosis (MS) in several countries, the impact of this …
therapies (DMTs) approved for multiple sclerosis (MS) in several countries, the impact of this …
Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple …
O Stüve, S Cepok, B Elias, A Saleh… - Archives of …, 2005 - jamanetwork.com
Background The anti-CD20 monoclonal antibody rituximab effectively depletes B
lymphocytes and has been successfully used in the therapy of immune-mediated disorders …
lymphocytes and has been successfully used in the therapy of immune-mediated disorders …
De-escalating rituximab dose results in stability of clinical, radiological, and serum neurofilament levels in multiple sclerosis
G Disanto, P Ripellino, GC Riccitelli… - Multiple Sclerosis …, 2021 - journals.sagepub.com
Background: Phase II and observational studies support the use of rituximab in multiple
sclerosis. Standard protocols are lacking, but studies suggest comparable efficacy between …
sclerosis. Standard protocols are lacking, but studies suggest comparable efficacy between …
Comparison of rituximab originator (MabThera®) to biosimilar (Truxima®) in patients with multiple sclerosis
T Perez, A Rico, C Boutière, A Maarouf… - Multiple Sclerosis …, 2021 - journals.sagepub.com
Background: Rituximab's originator MabThera® or Rituxan® has demonstrated high efficacy
in multiple sclerosis (MS). Because of the patent expiration, rituximab biosimilars have been …
in multiple sclerosis (MS). Because of the patent expiration, rituximab biosimilars have been …
[HTML][HTML] Efficacy, safety and patient reported outcomes in patients with active relapsing multiple sclerosis treated with ocrelizumab: final results from the PRO …
E Manchon, D Laplaud, S Vukusic, P Labauge… - Multiple Sclerosis and …, 2022 - Elsevier
Background Ocrelizumab, a humanized anti-CD20 monoclonal antibody, has been
approved in Europe for the treatment of adult patients with active relapsing multiple sclerosis …
approved in Europe for the treatment of adult patients with active relapsing multiple sclerosis …
Physician and patient treatment decision-making in relapsing-remitting multiple sclerosis in Europe and the USA
H Brown, S Gabriele, J White - Neurodegenerative disease …, 2018 - Taylor & Francis
Objective: To assess factors used in treatment decision-making for relapsing-remitting
multiple sclerosis in both the 5EU (UK/Germany/France/Italy/Spain) and the USA. Methods …
multiple sclerosis in both the 5EU (UK/Germany/France/Italy/Spain) and the USA. Methods …
Effect of lateral therapy switches to oral moderate-efficacy drugs in multiple sclerosis: a nationwide cohort study
MD Buron, T Kalincik, F Sellebjerg… - Journal of Neurology …, 2021 - jnnp.bmj.com
Background Switching between first-line disease-modifying therapies in patients with
clinically stable relapsing–remitting multiple sclerosis (RRMS) due to reasons other than …
clinically stable relapsing–remitting multiple sclerosis (RRMS) due to reasons other than …
Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial
B Weinstock-Guttman, R Bermel… - Multiple Sclerosis …, 2022 - journals.sagepub.com
Background: Many patients with multiple sclerosis (MS) experience suboptimal disease
control despite the use of disease-modifying therapy (DMT). Objective: To assess the …
control despite the use of disease-modifying therapy (DMT). Objective: To assess the …
[HTML][HTML] The Australian Multiple Sclerosis (MS) immunotherapy study: a prospective, multicentre study of drug utilisation using the MSBase platform
Objective To prospectively characterise treatment persistence and predictors of treatment
discontinuation in an Australian relapsing-remitting multiple sclerosis (RRMS) population …
discontinuation in an Australian relapsing-remitting multiple sclerosis (RRMS) population …